New cytotoxic agents and schedules for advanced breast cancer.
about
Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell linesA phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancerDoxorubicin and vinorelbine act independently via p53 expression and p38 activation respectively in breast cancer cell lines.
P2860
New cytotoxic agents and schedules for advanced breast cancer.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
New cytotoxic agents and schedules for advanced breast cancer.
@ast
New cytotoxic agents and schedules for advanced breast cancer.
@en
New cytotoxic agents and schedules for advanced breast cancer.
@nl
type
label
New cytotoxic agents and schedules for advanced breast cancer.
@ast
New cytotoxic agents and schedules for advanced breast cancer.
@en
New cytotoxic agents and schedules for advanced breast cancer.
@nl
prefLabel
New cytotoxic agents and schedules for advanced breast cancer.
@ast
New cytotoxic agents and schedules for advanced breast cancer.
@en
New cytotoxic agents and schedules for advanced breast cancer.
@nl
P2093
P1433
P1476
New cytotoxic agents and schedules for advanced breast cancer.
@en
P2093
C A Bunnell
H J Burstein
P304
P356
10.1016/S0093-7754(01)90129-0
P577
2001-08-01T00:00:00Z